Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus PENICILLIN G POTASSIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus PENICILLIN G POTASSIUM.
LAROTID vs PENICILLIN G POTASSIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Bactericidal: inhibits transpeptidases (penicillin-binding proteins) involved in bacterial cell wall synthesis, leading to cell lysis.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
1-4 million units IV every 4-6 hours; maximum 24 million units/day
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
0.5-1 hour in normal renal function; prolonged to 3-10 hours in anuria/end-stage renal disease.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Renal (60-90% as unchanged drug via tubular secretion and glomerular filtration); biliary (minor, <10%); fecal (minimal, <5%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic